“With Phase 3 readout expected in less than a year, Diamyd Medical is entering a critical stage in its development”, says Ulf Hannelius, CEO of Diamyd Medical. “Niklas Axelsson’s proven financial leadership in both global pharma and emerging biotech makes him an ideal addition to our executive team.”

Niklas Axelsson

Niklas Axelsson spent nearly two decades at AstraZeneca in senior financial roles, both in Sweden and internationally. Most recently, he served as CFO at the biotech firm Sprint Bioscience. Earlier in his career, he worked in corporate finance at Danske Bank.

“This is a particularly exciting moment to join Diamyd Medical”, says Niklas Axelsson. “With Phase 3 results on the horizon and a strong scientific and financial foundation, the company is well positioned for value creation. I look forward to supporting its transition into the next stage of growth.”

Niklas Axelsson succeeds Anna Styrud, who, as previously announced, has decided to leave Diamyd Medical after 15 years as CFO.